Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: walter reed army medical center experience 1988–1995 11The opinions and assertions contained herein are the private views of the authors and are not to be construed as reflecting the views of the U.S. Army or the Department of Defense

Objectives. To assess the ability of pretreatment and post-treatment prostate-specific antigen (PSA) measurements, clinical tumor stage, tumor grade, Gleason sum, race, age, and radiation dose to predict the recurrence of prostate cancer following external beam radiation therapy (XRT) since the introduction of PSA as a tumor marker at one...More